Verrica CEO to Present at TD Cowen Healthcare Conference
Event summary
- Verrica Pharmaceuticals CEO Jayson Rieger to present at TD Cowen 46th Annual Healthcare Conference on March 2, 2026.
- Live webcast available via Verrica’s investor relations page.
- Verrica’s YCANTH® (VP-102) approved for molluscum contagiosum, with development ongoing for common warts.
- Company licensed VP-315 for non-melanoma skin cancers from Lytix Biopharma AS.
The big picture
Verrica’s participation in the TD Cowen conference underscores its push to expand market awareness for YCANTH, while its licensing deal with Lytix Biopharma AS highlights strategic diversification into oncology. The company operates in a niche dermatology space with significant unmet needs, positioning it for growth if execution aligns with clinical and commercial milestones.
What we're watching
- Commercial Execution
- How Verrica will leverage conference exposure to accelerate YCANTH adoption in molluscum contagiosum.
- Pipeline Progress
- The pace at which VP-315 advances through development for non-melanoma skin cancers.
- Market Positioning
- Whether Verrica can establish dominance in dermatology therapeutics amid competition.
Related topics